EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Hong Kong Cuts Base Rate as HKMA Follows U.S. Federal Reserve Move 
Global Forex Markets Brace for Fed Decision as Yen Extends Weakness 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
CVS Health Signals Strong 2026 Profit Outlook Amid Turnaround Progress 
Modi and Trump Hold Phone Call as India Seeks Relief From U.S. Tariffs Over Russian Oil Trade 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Merck & Co Inc. revealed on Monday, Nov. 21, that it has acquired Imago BioSciences for $1.35 billion. The New Jersey-based pharmaceutical company is offering $36 per share in cash for the acquisition of the biotech firm, and this amount is said to be equivalent to almost 107% premium to its last closing price.
According to Reuters, this deal between Merck & Co. and Imago BioSciences drug developer is expected to close within the first quarter of 2023. This agreement is said to have opened several markets for the company.
Amid the buyout, Imago BioSciences is currently developing drugs for the treatment of diseases related to born marrow. The company uncovered a small molecule and brought it to phase 2 stage to find stronger evidence that suppressing lysine-specific demethylase 1 (LSD1) lowers the symptoms of myeloproliferative neoplasms or MPNs, which is a group of bone marrow cancers that can potentially develop into acute myeloid leukemia.
If the biotech firm is correct with its findings, bomedemstat will improve the results in the MPNs essential thrombocythemia, myelofibrosis, and polycythemia vera. Merck is interested in this discovery and bought into the idea; thus, it needs to buy Imago BioSciences.
Under the terms of the deal, through a subsidiary, Merck & Co. will set in motion a tender offer to buy all the remaining shares of Imago. Then again, it was noted that the closing of the offer will still be subject to some conditions, such as the expiration of the waiting period. According to the Hart-Scott-Rodino Antitrust Improvements Act, the tender of shares must represent a majority of Imago’s total number of available shares and other standard conditions.
“We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve,” Merck’s president and chief executive officer, Robert M. Davis, said in a press release. “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology.”
Dr. Hugh Y. Rienhoff, Jr., Imago BioSciences’ founder and CEO, also commented, “This milestone is a testament to more than a decade of pioneering research by Imago scientists and the entire Imago team’s unwavering dedication to improving the lives of patients. this agreement leverages Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat while providing important value for shareholders.”
